<button id="eiezk"><video id="eiezk"></video></button>

產(chǎn)品名稱(chēng)

CI 1033 - Canertinib dihydrochloride

產(chǎn)品貨號(hào)

Axon 1433 CAS [289499-45-2] MF C24H25ClFN5O3.2HClMW 558.86 Purity: 99% Soluble in water and DMSO Description An orally bioavailable tyrosine kinase inhibitor, targeting EGFR, irreversibly inhibiting their signal transduction functions and resulting in tumor cell apoptosis and suppression of tumor cell proliferation; water-soluble form References Certificates Categories Extra info PA. J?nne et al. Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non–Small-Cell Lung Cancer. J. Clinic. Oncology, 2007, 25(25), 3936-3944.? ? E Calvo et al. Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule. A Phase I Pharmacokinetic and Food Effect Study. Clinical Cancer Research 2004, 10, 7112-7120. ? LV Sequist. Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. The Oncologist, 2007, 12(3), 325-330.? Certificate of Analysis Material Safety Data Sheet Angiogenesis Apoptosis Cell Signaling & Oncology EGFR JAK-STAT RTK class I; EC 2.7.10.1 EGFR tyrosine kinase inhibitor Chemical name N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide dihydrochloride Parent CAS No. [267243-28-7] Order Size Unit Price Stock 5 mg €60.00 In Stock

產(chǎn)品價(jià)格

現(xiàn)貨詢(xún)價(jià)，電話(huà)：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

CI 1033 - Canertinib dihydrochloride

Based on 12 reference(s) in Google Scholar 9 10 12

Axon 1433

CAS [289499-45-2]

MF C24H25ClFN5O3.2HCl
MW 558.86

Purity: 99%
Soluble in water and DMSO

CI 1033

Description

An orally bioavailable tyrosine kinase inhibitor, targeting EGFR, irreversibly inhibiting their signal transduction functions and resulting in tumor cell apoptosis and suppression of tumor cell proliferation; water-soluble form

PA. J?nne et al. Multicenter, Randomized, Phase II Trial of CI-1033, an Irreversible Pan-ERBB Inhibitor, for Previously Treated Advanced Non–Small-Cell Lung Cancer. J. Clinic. Oncology, 2007, 25(25), 3936-3944.?

E Calvo et al. Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule. A Phase I Pharmacokinetic and Food Effect Study. Clinical Cancer Research 2004, 10, 7112-7120.

LV Sequist. Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. The Oncologist, 2007, 12(3), 325-330.?

Certificate of Analysis
Material Safety Data Sheet

Angiogenesis Apoptosis Cell Signaling & Oncology EGFR JAK-STAT RTK class I; EC 2.7.10.1

EGFR tyrosine kinase inhibitor

Chemical name

N-[4-(3-Chloro-4-fluoro-phenylamino)-7-(3-morpholin-4-yl-propoxy)-quinazolin-6-yl]-acrylamide dihydrochloride

Parent CAS No.

[267243-28-7]

產(chǎn)品資料

<button id="eiezk"><video id="eiezk"></video></button>